Literature DB >> 31989731

Chronic lung disease in children and adolescents with HIV: a case-control study.

Grace McHugh1, Andrea M Rehman2, Victoria Simms2, Carmen Gonzalez-Martinez3, Tsitsi Bandason1, Ethel Dauya1, Brewster Moyo3, Hilda Mujuru4, Jamie Rylance3, Evgeniya Sovershaeva5, Helen A Weiss2, Katharina Kranzer1,6,7, Jon Odland5,8, Rashida A Ferrand1,7.   

Abstract

OBJECTIVE: To describe the features of HIV-associated chronic lung disease (CLD) in older children and adolescents living with HIV and to examine the clinical factors associated with CLD. This is a post hoc analysis of baseline data from the BREATHE clinical trial (ClinicalTrials.gov, NCT02426112).
METHODS: Children and adolescents aged 6-19 years were screened for CLD (defined as a FEV1 z-score <-1 with no reversibility post-bronchodilation with salbutamol) at two HIV clinics in Harare, Zimbabwe, and Blantyre, Malawi. Eligible participants with CLD (cases) were enrolled, together with a control group without CLD [frequency-matched by age group and duration on antiretroviral therapy (ART)] in a 4:1 allocation ratio. A clinical history and examination were undertaken. The association between CLD and a priori-defined demographic and clinical covariates was investigated using multivariable logistic regression.
RESULTS: Of the 1585 participants screened, 419 (32%) had a FEV1 z-score <-1, of whom 347 were enrolled as cases [median age 15.3 years (IQR 12.7-17.7); 48.9% female] and 74 with FEV1 z-score >0 as controls [median age 15.6 years (IQR 12.1-18.2); 62.2% female]. Among cases, current respiratory symptoms including cough and shortness of breath were reported infrequently (9.3% and 1.8%, respectively). However, 152 (43.8%) of cases had a respiratory rate above the 90th centile for their age. Wasting and taking second-line ART were independently associated with CLD.
CONCLUSIONS: The presence of CLD indicates the need to address additional treatment support for youth living with HIV, alongside ART provision, to ensure a healthier adulthood.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  Africa; Afrique; HIV; VIH; adolescents; chronic lung disease; maladie pulmonaire chronique

Mesh:

Year:  2020        PMID: 31989731     DOI: 10.1111/tmi.13375

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  4 in total

1.  Risk factors for sustained virological non-suppression among children and adolescents living with HIV in Zimbabwe and Malawi: a secondary data analysis.

Authors:  Christi Jackson; Andrea M Rehman; Grace McHugh; Carmen Gonzalez-Martinez; Lucky G Ngwira; Tsitsi Bandason; Hilda Mujuru; Jon O Odland; Elizabeth L Corbett; Rashida A Ferrand; Victoria Simms
Journal:  BMC Pediatr       Date:  2022-06-11       Impact factor: 2.567

2.  Prevalence and antimicrobial resistance profiles of respiratory microbial flora in African children with HIV-associated chronic lung disease.

Authors:  Regina E Abotsi; Mark P Nicol; Grace McHugh; Victoria Simms; Andrea M Rehman; Charmaine Barthus; Slindile Mbhele; Brewster W Moyo; Lucky G Ngwira; Hilda Mujuru; Beauty Makamure; Justin Mayini; Jon Ø Odland; Rashida A Ferrand; Felix S Dube
Journal:  BMC Infect Dis       Date:  2021-02-25       Impact factor: 3.090

3.  Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial.

Authors:  Rashida A Ferrand; Grace McHugh; Andrea M Rehman; Hilda Mujuru; Victoria Simms; Edith D Majonga; Mark P Nicol; Trond Flaegstad; Tore J Gutteberg; Carmen Gonzalez-Martinez; Elizabeth L Corbett; Sarah L Rowland-Jones; Katharina Kranzer; Helen A Weiss; Jon O Odland
Journal:  JAMA Netw Open       Date:  2020-12-01

4.  Soluble biomarkers associated with chronic lung disease in older children and adolescents with perinatal HIV infection.

Authors:  Dan Hameiri-Bowen; Evgeniya Sovershaeva; Trond Flaegstad; Tore Jarl Gutteberg; Lucky Gift Ngwira; Victoria Simms; Andrea M Rehman; Grace Mchugh; Tsitsi Bandason; Rashida Abbas Ferrand; Sarah Rowland-Jones; Louis-Marie Yindom
Journal:  AIDS       Date:  2021-09-01       Impact factor: 4.632

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.